Breast cancer screening: New emphasis on shared decision-making between women and their doctors

December 10, 2018

An updated guideline on screening for breast cancer emphasizes shared decision-making between women and their doctors, supporting women to make an informed decision based on personal preferences when the balance between benefits and harms is uncertain. The guideline, released by the Canadian Task Force on Preventive Health Care, is published in CMAJ (Canadian Medical Association Journal).

Based on the latest evidence, including 29 studies assessing the value women place on anticipated benefits and harms from breast cancer screening, the guideline contains recommendations for women aged 40 to 74 years who are not at increased risk of breast cancer.

"Women have different values and preferences when it comes to balancing the benefits and harms of breast cancer screening," says Dr. Ainsley Moore vice-chair of the task force. "Those who may be concerned about the harms of screening, including overdiagnosis and invasive procedures, may choose not to be screened."

Breast cancer screening with mammography may reduce death from breast cancer, although it can also result in false positives, additional testing and possibly invasive procedures, as well as overdiagnosis, overtreatment and potential complications. Current evidence indicates a close balance between benefits and harms, leading to conditional recommendations based on patient preferences.

Recommendations: These recommendations are similar to those from the recent US Preventive Services Task Force guideline as well as the Canadian task force's 2011 guideline.

"These recommendations reflect the growing importance of shared decision-making between patients and physicians in preventive health screening, especially in situations like this where the balance between potential benefits and harms is uncertain," says Dr. Donna Reynolds, member of the task force. "While screening is recommended for women aged 50-74, some may choose not to be screened after weighing the benefits and harms with their physicians, and, conversely, some women under age 50 may choose screening."

The task force is an independent group of primary care and prevention specialists from across Canada. It notes that more high-quality evidence is needed on the benefits of breast cancer screening of women in all age groups.

"We hope this updated guideline will help women in Canada who are not at high risk of breast cancer make the right decision to be screened or not to screen," says Dr. Moore.

In a related commentary, Dr. Deborah Korenstein, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, writes, "The new recommendations on breast cancer screening from the Canadian Task Force on Preventive Health Care serve as a model for the important role of guidelines in promoting value in health care."

Dr. Korenstein says that, compared with other international guidelines, the task force's guideline "is alone among similar guidelines in noting in the main recommendation for all age groups that 'the decision to undergo screening is conditional on the relative value that a woman places on possible benefits and harms.' This overt across-the-board acknowledgement of the primacy of the patient world view encourages Canadian physicians to prioritize patient-centred care and value."

For the full guideline and additional patient and physician decision-making tools, visit http://www.canadiantaskforce.ca.

"Recommendations on screening for breast cancer in women aged 40-74 years who are not at increased risk for breast cancer" is published December 10, 2018.
-end-
Podcast permanent links:

English: https://soundcloud.com/cmajpodcasts/180463-guide-eng

French: https://soundcloud.com/cmajpodcasts/180463-guide-fre

Canadian Medical Association Journal

Related Breast Cancer Articles from Brightsurf:

Oncotarget: IGF2 expression in breast cancer tumors and in breast cancer cells
The Oncotarget authors propose that methylation of DVDMR represents a novel epigenetic biomarker that determines the levels of IGF2 protein expression in breast cancer.

Breast cancer: AI predicts which pre-malignant breast lesions will progress to advanced cancer
New research at Case Western Reserve University in Cleveland, Ohio, could help better determine which patients diagnosed with the pre-malignant breast cancer commonly as stage 0 are likely to progress to invasive breast cancer and therefore might benefit from additional therapy over and above surgery alone.

Partial breast irradiation effective treatment option for low-risk breast cancer
Partial breast irradiation produces similar long-term survival rates and risk for recurrence compared with whole breast irradiation for many women with low-risk, early stage breast cancer, according to new clinical data from a national clinical trial involving researchers from The Ohio State University Comprehensive Cancer Center - Arthur G.

Breast screening linked to 60 per cent lower risk of breast cancer death in first 10 years
Women who take part in breast screening have a significantly greater benefit from treatments than those who are not screened, according to a study of more than 50,000 women.

More clues revealed in link between normal breast changes and invasive breast cancer
A research team, led by investigators from Georgetown Lombardi Comprehensive Cancer Center, details how a natural and dramatic process -- changes in mammary glands to accommodate breastfeeding -- uses a molecular process believed to contribute to survival of pre-malignant breast cells.

Breast tissue tumor suppressor PTEN: A potential Achilles heel for breast cancer cells
A highly collaborative team of researchers at the Medical University of South Carolina and Ohio State University report in Nature Communications that they have identified a novel pathway for connective tissue PTEN in breast cancer cell response to radiotherapy.

Computers equal radiologists in assessing breast density and associated breast cancer risk
Automated breast-density evaluation was just as accurate in predicting women's risk of breast cancer, found and not found by mammography, as subjective evaluation done by radiologists, in a study led by researchers at UC San Francisco and Mayo Clinic.

Blood test can effectively rule out breast cancer, regardless of breast density
A new study published in PLOS ONE demonstrates that Videssa® Breast, a multi-protein biomarker blood test for breast cancer, is unaffected by breast density and can reliably rule out breast cancer in women with both dense and non-dense breast tissue.

Study shows influence of surgeons on likelihood of removal of healthy breast after breast cancer dia
Attending surgeons can have a strong influence on whether a patient undergoes contralateral prophylactic mastectomy after a diagnosis of breast cancer, according to a study published by JAMA Surgery.

Young breast cancer patients undergoing breast conserving surgery see improved prognosis
A new analysis indicates that breast cancer prognoses have improved over time in young women treated with breast conserving surgery.

Read More: Breast Cancer News and Breast Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.